Collegium Pharmaceutical (COLL)

• Market cap: $868M
• 1 day: -0.04%
• 5 days: 8.13%
• 1 month: -8.97%
• 3 months: -19.01%
• 6 months: -30.62%
• Year to date: -5.66%
• 1 year: -23.81%
• 5 years: 38.44%
• 10 years: 119.77%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Jornay, Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.

Employees: 357

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

155% more call options, than puts

Call options by funds: $707K | Put options by funds: $277K

0% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 1 (+0) [Q4]

4% less funds holding

Funds holding: 248 [Q3] → 238 (-10) [Q4]

4.31% less ownership

Funds ownership: 119.5% [Q3] → 115.19% (-4.31%) [Q4]

18% less first-time investments, than exits

New positions opened: 36 | Existing positions closed: 44

23% less repeat investments, than reductions

Existing positions increased: 71 | Existing positions reduced: 92

28% less capital invested

Capital invested by funds: $1.49B [Q3] → $1.06B (-$422M) [Q4]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $36 33% upside
• Avg. target: $44 63% upside
• High target: $50 85% upside

3 analyst ratings

• positive: 2 67%
• neutral: 1 33%
• negative: 0 0%

Needham Serge Belanger 36% 1-year accuracy 44 / 123 met price target	70% upside $46	Buy Reiterated	9 Apr 2025
HC Wainwright & Co. Oren Livnat 48% 1-year accuracy 24 / 50 met price target	85% upside $50	Buy Reiterated	24 Mar 2025
Piper Sandler David Amsellem 44% 1-year accuracy 14 / 32 met price target	33% upside $36	Neutral Maintained	4 Feb 2025